Astria Therapeutics, Inc.

NasdaqGM:ATXS Stok Raporu

Piyasa değeri: US$527.1m

Astria Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Astria Therapeutics CEO'su Jill Milne, Jun2008 tarihinde atandı, in görev süresi 16.42 yıldır. in toplam yıllık tazminatı $ 2.96M olup, şirket hissesi ve opsiyonları dahil olmak üzere 20.4% maaş ve 79.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.008% ine doğrudan sahiptir ve bu hisseler $ 40.90K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.7 yıl ve 9.1 yıldır.

Anahtar bilgiler

Jill Milne

İcra Kurulu Başkanı

US$3.0m

Toplam tazminat

CEO maaş yüzdesi20.4%
CEO görev süresi16.4yrs
CEO sahipliği0.008%
Yönetim ortalama görev süresi4.7yrs
Yönetim Kurulu ortalama görev süresi9.1yrs

Son yönetim güncellemeleri

Recent updates

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

Nov 14
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Jul 11
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Jun 24

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Feb 04

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Dec 10
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Jul 27
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Apr 03
We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Nov 30
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Aug 01
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Jul 15

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Jun 30

Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital

Jun 15

Catabasis Pharma shares surge after Quellis Biosciences deal

Jan 29

Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Dec 10
Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 29

CEO Tazminat Analizi

Jill Milne'un ücretlendirmesi Astria Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$100m

Jun 30 2024n/an/a

-US$93m

Mar 31 2024n/an/a

-US$82m

Dec 31 2023US$3mUS$602k

-US$73m

Sep 30 2023n/an/a

-US$55m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022US$2mUS$568k

-US$52m

Sep 30 2022n/an/a

-US$48m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$65m

Dec 31 2021US$3mUS$536k

-US$219m

Sep 30 2021n/an/a

-US$219m

Jun 30 2021n/an/a

-US$222m

Mar 31 2021n/an/a

-US$199m

Dec 31 2020US$1mUS$520k

-US$37m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$1mUS$501k

-US$26m

Sep 30 2019n/an/a

-US$26m

Jun 30 2019n/an/a

-US$25m

Mar 31 2019n/an/a

-US$24m

Dec 31 2018US$1mUS$476k

-US$26m

Sep 30 2018n/an/a

-US$25m

Jun 30 2018n/an/a

-US$27m

Mar 31 2018n/an/a

-US$27m

Dec 31 2017US$633kUS$462k

-US$27m

Tazminat ve Piyasa: Jill 'nin toplam tazminatı ($USD 2.96M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.18M ).

Tazminat ve Kazançlar: Jill şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jill Milne (56 yo)

16.4yrs

Görev süresi

US$2,955,504

Tazminat

Ms. Jill C. Milne, PhD is a Co-founder of Astria Therapeutics, Inc. (formerly known as Catabasis Pharmaceuticals, Inc.), has been its Director, President and Chief Executive Officer since June 2008. She se...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Jill Milne
Co-Founder16.4yrsUS$2.96m0.0078%
$ 40.9k
Noah Clauser
CFO & Treasurer4.9yrsUS$1.35m0%
$ 0
Christopher Morabito
Chief Medical Officer2.3yrsUS$1.32m0%
$ 0
Benjamin Harshbarger
Chief Legal Officer4.4yrsUS$845.83k0%
$ 0
Keri McGrail
Senior Vice President of Human Resources3.6yrsVeri yokVeri yok
Andrea Matthews
Chief Business Officer7.2yrsVeri yokVeri yok
Andrew Komjathy
Chief Commercial Officer5.2yrsVeri yokVeri yok
John Ruesch
Senior Vice President of Pharmaceutical Sciences & Technical Operations1.3yrsVeri yokVeri yok

4.7yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: ATXS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.7 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Jill Milne
Co-Founder16.4yrsUS$2.96m0.0078%
$ 40.9k
Michael Kishbauch
Independent Director8.6yrsUS$157.67k0%
$ 0
Edward Scolnick
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Kenneth Bate
Independent Chairman of the Board10.8yrsUS$194.17kVeri yok
Arthur Rubenstein
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Gregory Lapointe
Independent Director5.8yrsUS$163.67k0%
$ 0
Johannes Jacob Kastelein
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Michael Jirousek
Member of Scientific Advisory Board9.1yrsUS$589.63kVeri yok
Jay Horton
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Roger Ulrich
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Eric Brass
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Sekar Kathiresan
Member of Scientific Advisory Boardno dataVeri yokVeri yok

9.1yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ATXS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.1 yıldır).